Literature DB >> 8564959

Homozygous deletion map at 18q21.1 in pancreatic cancer.

S A Hahn1, A T Hoque, C A Moskaluk, L T da Costa, M Schutte, E Rozenblum, A B Seymour, C L Weinstein, C J Yeo, R H Hruban, S E Kern.   

Abstract

Absolute genetic differences between neoplastic and nonneoplastic cells can be discerned at sites of homozygous deletions. These deletions are of critical interest because they might be useful in the identification of defective biochemical pathways in neoplastic cells, and subsequently for the development of new treatment strategies in human cancer. We identified an area at 18q21.1 involved by homozygous deletions in 30% of pancreatic carcinomas. To characterize the homozygous deletions, we constructed a detailed physical map of nearly 2 Mb, containing yeast artificial chromosomes, P1-derived artificial chromosomes, cosmids and 24 sequence-tagged sites. The homozygously deleted are contained a new candidate tumor-suppressor gene (DPC4). To date, 23 (64%) of 35 pancreatic carcinomas carry at least one homozygous deletion at a published locus. The study of the total gene content of these loci, facilitated by the sequence-tagged site markers and maps of these regions, should help to reveal the absolute biochemical differences between neoplastic and nonneoplastic cells for a common human tumor.

Entities:  

Mesh:

Year:  1996        PMID: 8564959

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  74 in total

1.  Loss of heterozygosity or intragenic mutation, which comes first?

Authors:  R E Wilentz; P Argani; R H Hruban
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

2.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

3.  Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease.

Authors:  A Maitra; K Molberg; J Albores-Saavedra; G Lindberg
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

4.  K-ras mutations and allelic loss at 5q and 18q in the development of human pancreatic cancers.

Authors:  K Sugio; K Molberg; J Albores-Saavedra; A K Virmani; Y Kishimoto; A F Gazdar
Journal:  Int J Pancreatol       Date:  1997-06

5.  Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells.

Authors:  Shujie Zhao; Yubao Wang; Lin Cao; Michel M Ouellette; James W Freeman
Journal:  Int J Cancer       Date:  2010-11-01       Impact factor: 7.396

Review 6.  Structural determinants of Smad function in TGF-β signaling.

Authors:  Maria J Macias; Pau Martin-Malpartida; Joan Massagué
Journal:  Trends Biochem Sci       Date:  2015-04-29       Impact factor: 13.807

7.  The structural basis of molecular genetic deletions. An integration of classical cytogenetic and molecular analyses in pancreatic adenocarcinoma.

Authors:  D J Brat; S A Hahn; C A Griffin; C J Yeo; S E Kern; R H Hruban
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

8.  A mathematical model quantifies proliferation and motility effects of TGF-β on cancer cells.

Authors:  Shizhen Emily Wang; Peter Hinow; Nicole Bryce; Alissa M Weaver; Lourdes Estrada; Carlos L Arteaga; Glenn F Webb
Journal:  Comput Math Methods Med       Date:  2009-03       Impact factor: 2.238

Review 9.  Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer.

Authors:  Barbara Jung; Jonas J Staudacher; Daniel Beauchamp
Journal:  Gastroenterology       Date:  2016-10-20       Impact factor: 22.682

10.  Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents.

Authors:  Andreas Palagyi; Kornelia Neveling; Ursula Plinninger; Andreas Ziesch; Bianca-Sabrina Targosz; Gerald U Denk; Stephanie Ochs; Antonia Rizzani; Daniel Meier; Wolfgang E Thasler; Helmut Hanenberg; Enrico N De Toni; Florian Bassermann; Claus Schäfer; Burkhard Göke; Detlev Schindler; Eike Gallmeier
Journal:  Mol Cancer       Date:  2010-05-28       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.